Posttraumatic Stress Disorder
Conditions
Keywords
Posttraumatic Stress Disorder, Escitalopram, Magnetic Resonance Imaging, BDNF
Brief summary
The objectives of the current study are 1. to evaluate the efficacy of escitalopram in treatment for post-traumatic stress disorder, 2. to find the structural changes of brain using magnetic resonance imaging and its association with the symptoms reduction, and 3. to look at the differences of brain imaging findings and symptoms changes according to genetic differences of brain-derived neurotrophic factor (a biological molecule facilitating neuronal growth in human).
Interventions
0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
Sponsors
Seoul National University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 18-65 year-old male or female * PTSD diagnosed by SCID-IV
Exclusion criteria
* Previous or current treatment history for PTSD * Neurologic disease (eg., epilepsy, infarct, multiple sclerosis, brain tumor) * Any other axis I psychiatric disorder diagnosed by SCID-IV * Borderline personality disorder or antisocial personality disorder * IQ below 80 * Any contraindication to MRI scan * Any current psychotropic medication * Unstable medical illness or severe abnormality in laboratory test at screening assessment * Women who are pregnant, breastfeeding, or planning pregnancy * Any contraindications to drug used in the study (e.g., allergy, intolerance, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes from baseline in brain structure, function, and biochemical metabolism, analyzed using the computational approach | Baseline, 8th weeks |
| Change from baseline in Clinician-administered PTSD scale scores at 1st week | Baseline, 1st week |
| Change from baseline in Clinician-administered PTSD scale scores at 4th weeks | Baseline, 4th weeks |
| Change from baseline in Clinician-administered PTSD scale scores at 8th weeks | Baseline, 8th weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in Hamilton depression rating scale scores at 8th weeks | Baseline, 8th weeks |
| Change from baseline in Hamilton depression rating scale scores at 1st week | Baseline, 1st week |
| Change from baseline in Hamilton anxiety rating scale scores at 8th weeks | Baseline, 8th weeks |
| Change from baseline in Hamilton anxiety rating scale scores at 4th weeks | Baseline, 4th weeks |
| Change from baseline in Hamilton anxiety rating scale scores at 1st week | Baseline, 1st week |
| Number of participants with adverse events | 1st week |
| Change from baseline in Hamilton depression rating scale scores at 4th weeks | Baseline, 4th weeks |
Countries
South Korea
Contacts
Primary ContactJunghyun H Lee, MD, MS
Outcome results
None listed